AsianScientist (Dec. 23, 2015) – Researchers have used antisense oligonucleotides (ASOs) against the protein MDM4 to suppress cancer growth. Their findings, which may pave the way for the development of novel cancer therapeutics, were published in the Journal of Clinical Investigation.
To multiply, cancer cells need to inhibit the tumor suppressor p53. In the case of skin-related melanoma, it had been proposed that tumor cells use the overexpression of MDM4 to inhibit p53. As MDM4 is highly expressed in cancer cells but not in normal adult tissues, it represents a promising therapeutic target.
The research team had previously proven MDM4’s ability to bind directly to p53 and inhibit its tumor suppressor function in metastatic melanoma, a rare but most aggressive type of skin cancer. While the study served as a useful proof-of-concept therapeutics, it was still unclear how the findings could be useful in a clinical setting.
Finding small molecules that can interfere directly with MDM4 function has proven to be an enormous challenge and there is no clinically-compatible alternative to selectively and efficiently disrupt the MDM4-p53 complexes. There is also an increasing body of evidence that MDM4 can facilitate tumor formation without necessarily binding to p53.
“As an alternative to pharmacological inhibition of the MDM4-p53 protein interaction we reasoned that targeting MDM4 protein abundance—rather than its interaction with p53—may be easier to achieve pharmacologically,” said Professor Jean-Christophe Marine, who heads the Flanders Institute for Biotechnology (VIB) and has been studying MDM4 for several years
“In addition, it may also have broader and more robust anti-tumor effects as this would inhibit both p53-dependent and independent oncogenic functions of MDM4.”
Headed by Dr. Ernesto Guccione, the laboratory in the Institute of Molecular and Cell Biology (IMCB) has been researching on the use of ASOs technology to interfere with pre-mRNA splicing and protein abundance. Leveraging IMCB’s expertise in the field of ASOs and through a collaborative effort, the scientists found in the latest study that targeting MDM4 protein abundance using ASOs could impair tumor growth, reduce cell proliferation and increase cell death.
This discovery suggests that MDM4 is indeed a promising clinically-compatible therapeutic target which can be suppressed with ASOs, and offers alternative therapeutic avenues not only for melanoma, but also for a wide range of other MDM4-expressing cancers such as breast cancer, ovarian cancer, B-cell lymphoma or retinoblastoma.
Guccione, Senior Principal Investigator at IMCB and co-lead for the study, said, “This work is a good example of how ASOs can target proteins that are hard to inhibit by traditional approaches such as small molecule inhibitors, and it greatly expands our options for therapeutic intervention.”
The article can be found at: Dewaele et al. (2015) Antisense Oligonucleotide–mediated MDM4 Exon 6 Skipping Impairs Tumor Growth.
———
Source: A*STAR; Photo: Yale Rosen/Flickr/CC.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.